| HR | 95% CI | p value | |
---|---|---|---|---|
LFS | ||||
 UD vs MSD | 0.96 | 0.79 | 1.17 | 0.68 |
 Age ≥50 years | 1.17 | 0.98 | 1.40 | 0.09 |
 Year of Tx > median | 1.02 | 0.85 | 1.23 | 0.83 |
 Cytogenetics | ||||
  Poor vs intermediate | 1.61 | 1.24 | 2.09 | <10−3 |
  Missing vs intermediate | 1.18 | 0.96 | 1.46 | 0.11 |
 CMV patient positive | 1.19 | 0.98 | 1.44 | 0.09 |
 CMV donor positive | 0.99 | 0.82 | 1.19 | 0.90 |
 Female to male | 1.03 | 0.84 | 1.26 | 0.77 |
 Diag to Tx > median | 1.21 | 1.02 | 1.44 | 0.03 |
 KPS > 90% | 0.67 | 0.56 | 0.80 | <10−5 |
 In vivo T depletion | 1.02 | 0.84 | 1.26 | 0.81 |
 Conditioning regimen (ref = MAC) | ||||
  RIC vs MAC | 0.89 | 0.73 | 1.08 | 0.25 |
  Sequential strategy vs MAC | 0.91 | 0.69 | 1.21 | 0.53 |
OS | ||||
 UD vs MSD | 1.02 | 0.83 | 1.25 | 0.87 |
 Age ≥50 years | 1.33 | 1.10 | 1.61 | 0.004 |
 Year of Tx > median | 1.02 | 0.84 | 1.24 | 0.83 |
 Cytogenetics | ||||
  Poor vs intermediate | 1.55 | 1.19 | 2.03 | 0.001 |
  Missing vs intermediate | 1.23 | 0.99 | 1.53 | 0.06 |
 CMV patient positive | 1.28 | 1.04 | 1.58 | 0.02 |
 CMV donor positive | 0.97 | 0.80 | 1.19 | 0.79 |
 Female to male | 1.06 | 0.86 | 1.32 | 0.57 |
 Diag to Tx > median | 1.20 | 1.00 | 1.44 | 0.05 |
 KPS >90% | 0.65 | 0.54 | 0.79 | <10−5 |
 In vivo T depletion | 0.94 | 0.76 | 1.16 | 0.55 |
 Conditioning regimen (ref = MAC) | ||||
  RIC vs MAC | 0.83 | 0.67 | 1.02 | 0.08 |
  Sequential strategy vs MAC | 0.81 | 0.60 | 1.09 | 1.16 |
RI | ||||
 UD vs MSD | 0.89 | 0.71 | 1.12 | 0.33 |
 Age ≥50 years | 0.99 | 0.80 | 1.22 | 0.94 |
 Year of Tx >median | 0.95 | 0.77 | 1.18 | 0.66 |
 Cytogenetics | ||||
  Poor vs intermediate | 1.74 | 1.30 | 2.33 | <10−3 |
  Missing vs intermediate | 1.10 | 0.86 | 1.40 | 0.45 |
 CMV patient positive | 1.07 | 0.86 | 1.33 | 0.56 |
 CMV donor positive | 0.97 | 0.78 | 1.20 | 0.75 |
 Female to male | 1.08 | 0.86 | 1.37 | 0.51 |
 Diag to Tx > median | 1.29 | 1.06 | 1.58 | 0.01 |
 KPS >90% | 0.77 | 0.62 | 0.95 | 0.01 |
 In vivo T depletion | 1.10 | 0.87 | 1.40 | 0.43 |
 Conditioning regimen (ref = MAC) | ||||
  RIC vs MAC | 1.03 | 0.81 | 1.29 | 0.83 |
  Sequential strategy vs MAC | 0.98 | 0.71 | 1.35 | 0.89 |
NRM | ||||
 UD vs MSD | 1.30 | 0.91 | 1.86 | 0.14 |
 Age ≥50 years | 1.77 | 1.27 | 2.47 | 0.001 |
 Year of Tx > median | 1.18 | 0.84 | 1.64 | 0.33 |
 Cytogenetics | ||||
  Poor vs intermediate | 1.53 | 0.91 | 2.59 | 0.11 |
  Missing vs intermediate | 1.44 | 0.98 | 2.13 | 0.06 |
 CMV patient positive | 1.68 | 1.14 | 2.47 | 0.01 |
 CMV donor positive | 1.06 | 0.75 | 1.49 | 0.76 |
 Female to male | 1.01 | 0.70 | 1.47 | 0.95 |
 Diag to Tx > median | 1.06 | 0.77 | 1.45 | 0.72 |
 KPS >90% | 0.48 | 0.35 | 0.66 | <10−5 |
 In vivo T depletion | 0.89 | 0.62 | 1.29 | 0.54 |
 Conditioning regimen (ref = MAC) | ||||
  RIC vs MAC | 0.59 | 0.41 | 0.85 | 0.005 |
  Sequential strategy vs MAC | 0.82 | 0.48 | 1.38 | 0.45 |
cGVHD | ||||
 UD vs MSD | 1.22 | 0.86 | 1.74 | 0.26 |
 Age ≥50 years | 1.06 | 0.76 | 1.47 | 0.73 |
 Year of Tx > median | 1.06 | 0.76 | 1.48 | 0.72 |
 Cytogenetics | ||||
  Poor vs intermediate | 1.01 | 0.64 | 1.59 | 0.96 |
  Missing vs intermediate | 0.82 | 0.58 | 1.16 | 0.26 |
 CMV patient positive | 1.24 | 0.87 | 1.75 | 0.23 |
 CMV donor positive | 1.07 | 0.76 | 1.51 | 0.70 |
 Female to male | 1.53 | 1.07 | 2.19 | 0.02 |
 Diag to Tx > median | 0.85 | 0.62 | 1.17 | 0.32 |
 KPS >90% | 1.01 | 0.72 | 1.41 | 0.97 |
 In vivo T depletion | 0.51 | 0.35 | 0.74 | 0.001 |
 Conditioning regimen (ref = MAC) | ||||
  RIC vs MAC | 1.20 | 0.83 | 1.73 | 0.32 |
  Sequential strategy vs MAC | 1.07 | 0.63 | 1.80 | 0.81 |